PRUNUS takes bold steps for the future healthcare. By nailing down the key biological differences between cancer and normal cells, PRUNUS is pioneering an entirely new way of targeting cancer (Patent Pending). We won't miss the chance when cancer cells expose their weakness.

Cancer therapeutics should target only cancer cells, leaving healthy cells unaffected. We believe that our challenge would lead to new sustainable healthcare options able to improve treatment outcomes as well as quality of life.